Samuel L Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/248088/publications.pdf

Version: 2024-02-01

34 papers 1,416 citations

430874 18 h-index 477307 29 g-index

38 all docs

38 docs citations

38 times ranked

2574 citing authors

#	Article	IF	CITATIONS
1	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55.	1.4	171
2	Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nature Communications, 2019, 10, 1295.	12.8	133
3	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
4	Investigation of American Association of Physicists in Medicine Report 204 Size-specific Dose Estimates for Pediatric CT Implementation. Radiology, 2012, 265, 832-840.	7. 3	117
5	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	9.4	109
6	Use of Water Equivalent Diameter for Calculating Patient Size and Size-Specific Dose Estimates (SSDE) in CT: The Report of AAPM Task Group 220. AAPM Report, 2014, 2014, 6-23.	2.0	91
7	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	9.4	88
8	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
9	Size-specific dose estimate (SSDE) provides a simple method to calculate organ dose for pediatric CT examinations. Medical Physics, 2014, 41, 071917.	3.0	72
10	Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance. Neoplasia, 2019, 21, 822-836.	5.3	43
11	Pediatric CT: Implementation of ASIR for Substantial Radiation Dose Reduction While Maintaining Pre-ASIR Image Noise. Radiology, 2014, 270, 223-231.	7.3	41
12	The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Molecular Cancer Research, 2019, 17, 895-906.	3.4	40
13	Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends in Genetics, 2022, 38, 194-208.	6.7	39
14	How to Appropriately Calculate Effective Dose for CT Using Either Size-Specific Dose Estimates or Dose-Length Product. American Journal of Roentgenology, 2015, 204, 953-958.	2.2	37
15	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	12.8	35
16	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	12.8	31
17	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2021, 2, 819-834.	13.2	24
18	Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 2022, 139, 3519-3531.	1.4	20

#	Article	IF	CITATIONS
19	Current state of practice regarding digital radiography exposure indicators and deviation indices: Report of <scp>AAPM</scp> Imaging Physics Committee Task Group 232. Medical Physics, 2018, 45, e1146-e1160.	3.0	19
20	Ultralow dose computed tomography attenuation correction for pediatric PET CT using adaptive statistical iterative reconstruction. Medical Physics, 2015, 42, 558-566.	3.0	18
21	Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint. Cancer Cell, 2021, 39, 83-95.e4.	16.8	18
22	The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State. Cancer Research, 2019, 79, 2892-2908.	0.9	17
23	A`one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer. Translational Oncology, 2021, 14, 100946.	3.7	8
24	JOURNAL CLUB: A Comprehensive Risk Assessment Method for Pediatric Patients Undergoing Research Examinations Using Ionizing Radiation: How We Answered the Institutional Review Board. American Journal of Roentgenology, 2015, 204, W510-W518.	2.2	7
25	The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233.	2.6	7
26	Development and validation of an open source Monte Carlo dosimetry model for wideâ€beam CT scanners using Fluka. Journal of Applied Clinical Medical Physics, 2019, 20, 132-147.	1.9	6
27	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
28	Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies. Genome Medicine, 2021, 13, 170.	8.2	5
29	Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237.	1.4	1
30	Reply to: Radiation dose reduction thanks to split-bolus multi-1 detector computer tomography (MDCT) in children with non-thoracic neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1867-1867.	1.5	0
31	Abstract 2289: Empowering point-and-click genomic analysis with large pediatric genomic reference data on St. Jude Cloud. , 2021, , .		0
32	Abstract 633: Thiopurines and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse., 2021,,.		0
33	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer., 2021,,.		0
34	Mutational Landscape and Temporal Evolution during Treatment of Relapsed Acute Lymphoblastic Leukemia. Blood, 2018, 132, 917-917.	1.4	0